In this analysis, the 21-gene signature was associated with a substantial reduction in CT usage and is more effective and less costly when compared to SoC (34); therefore, the results were similar to those observed in postmenopausal women with HR+, HER2−, N1, early BC in our analysis. The gene discussed is HR; the disease is breast cancer.